Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 16, Issue 35, 2010, Pages 4410-4415

  Liu, Hui ^a   Li, Peng ^a   Zhai, Yun ^a   Qu, Chun Feng ^b   Zhang, Li Jie ^a   Tan, Yu Fen ^a   Li, Ning ^a   Ding, Hui Guo ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Diagnosis; Glypican 3; Hepatocellular carcinoma; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3;

ADULT; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SERUM;

EID: 77957558765     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i35.4410     Document Type: Article

References (27)

1. Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Shibata K, Ohta M, Kitano S. Short-and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol 2008; 15: 1670-1676
2. Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 418-424
3. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-1118
4. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M, Stein K. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008; 98: 1166-1175
5. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422
6. Ji Z, Sun ZT, Wang LQ, Ding GS, Chu PP, Li FM. [Characteristics of AFP serology in early PHC and the high risk group (author's transl)] Zhonghua Zhongliu Zazhi 1979; 1: 96-100
7. Lopez JB. Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev 2005; 26: 65-79
8. Yang BH. Chinese Society of Liver Cancer: Clinical diagnosis and staging criteria for primary hepatocellular carcinoma. Zhongguo Ganzangbing Zazhi 2001; 9: 324-330
9. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasialike nodules. Am J Surg Pathol 2006; 30: 1405-1411
10. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008; 14: 470-477
11. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6: 133-137
12. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark 2008; 4: 19-33
13. Zhou XP, Wang HY, Yang GS, Chen ZJ, Li BA, Wu MC. Cloning and expression of MXR7 gene in human HCC tissue. World J Gastroenterol 2000; 6: 57-60
14. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008; 21: 1011-1018
15. Kim KA, Lee JS, Jung ES, Kim JY, Bae WK, Kim NH, Moon YS. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development] Korean J Gastroenterol 2006; 48: 321-326
16. Hirohashi S, Ishak KG, Kojiro M, Wanless IR, Theise ND, Tsukuma H, Blum HE, Deugnier Y, Laurent Puig P, Fischer HP. Hepatocellular carcinoma. In: Aaltonen LA, Hamilton SR, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000: 159-172
17. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, Sun Z. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002; 36: 1214-1220
18. Gao JD, Shao YF, Xu Y, Ming LH, Wu ZY, Liu GT, Wang XH, Gao WH, Sun YT, Feng XL, Liang LM, Zhang YH, Sun ZT. Tight association of hepatocellular carcinoma with HBV infection in North China. Hepatobiliary Pancreat Dis Int 2005; 4: 46-49
19. Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, Wu J, Zhang F, Zhang Y, Wang Y, Bi S. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 2009; 4: e8467
20. Madhoun MF, Fazili J, Bright BC, Bader T, Roberts DN, Bronze MS. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci 2010; 339: 169-173
21. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, Sesti R, Tripi S, Montalto G. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003; 23: 1747-1753
22. Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer 2008; 44: 528-538
23. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004; 127: S113-S119
24. Yang BH, Xia JL, Huang LW, Tang ZY, Chen MS, Li JQ, Liang AM, Mo QG, Lu HS, Dai CL, Yan LN, Yu ZJ, Rao RS, Li LQ, Su ZX, Fang ZW. [Changes of clinical aspect of primary liver cancer in China during the past 30 years-control study for 3,250 cases with primary liver cancer] Zhonghua Yixue Zazhi 2003; 83: 1053-7105
25. Baek YH, Lee JH, Jang JS, Lee SW, Han JY, Jeong JS, Choi JC, Kim HY, Han SY. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 2009; 56: 763-767
26. Wang DS, Ding HG, Li Z, Xin YM, Zhang B, Li N, Chen DX, Yin JM. The diagnostic value of combination with GPC3 and AFP in hepatocellular carcinomas. Zhonghua Jianyan Yixue Zazhi 2007; 10: 1169-1171
27. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, Shen F, Tang ZY, Wang XW. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 2007; 13: s1133-1139